Argentum and Cosmo Settle Patent Dispute Over UCERIS®

NEW YORK, April 24, 2018 /PRNewswire/ -- Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement agreement with Cosmo Technologies Limited related to Argentum’s inter partes review petition challenging an Orange Book-listed patent for UCERIS® (budesonide).

Argentum filed its IPR petition on October 20, 2018. Argentum and Cosmo entered into a settlement agreement on April 19, 2018, prior to a decision on Argentum’s petition by the Patent Trial & Appeal Board. Details concerning the settlement have not been disclosed.

The patent that was being challenged by Argentum (U.S. Patent No. 9,320,716) is currently the subject of the following ongoing litigations: Cosmo Technologies Limited, Valeant Pharmaceuticals International, and Valeant Pharmaceuticals Luxembourg S.A. R.L. v Lupin Ltd. and Lupin Pharmaceuticals, Inc., 15-cv-00669 (D. Del.), and Cosmo Technologies Limited, Valeant Pharmaceuticals International, and Valeant Pharmaceuticals Luxembourg S.A. R.L. v Sun Pharmaceutical Industries, Ltd., Sun Pharma Global FZE, and Sun Pharmaceutical Industries, Inc., 15-cv-00669 (D.N.J.). The ‘716 patent was also the subject of Cosmo Technologies Limited, Valeant Pharmaceuticals International, and Valeant Pharmaceuticals Luxembourg S.A. R.L. v. Mylan Pharmaceuticals, Inc., 16-cv-00152 (D. Del.).

UCERIS® is a registered trademark of Salix Pharmaceuticals or its affiliates.

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices. www.argentumpharmaceuticals.com

CONTACT: Jeffrey Gardner, 646-405-6300, jgardner@agpharm.com